Summit Therapeutics' Lung Cancer Drug Rejected by FDA
FDA rejected Summit Therapeutics' ivonescimab BLA for lung cancer because progression-free survival improvements do not establish effectiveness without overall survival gains. The stock fell to a 52-w
FDA Rejects Summit Therapeutics' Ivonescimab BLA
NEW YORK, November 17 —
Both Co-CEOs of Summit Therapeutics Inc. (SMMT) exercised stock options at $1.06 per share on November 16, the day the FDA rejected the ivonescimab BLA for lung cancer. The agency ruled that progression-free survival improvement without overall survival gains could not establish effectiveness, pushing shares to a 52-week intraday low.
- FDA rejected the BLA; PFS gains without overall survival improvement could not establish effectiveness, per the agency.
- SMMT fell 16.47% on November 16 and an additional 8.93% on November 17, reaching $10.64.
- Co-CEOs Robert Duggan and Mahkam Zanganeh each exercised 500,000 options at $1.06 per share on the rejection day.
Why PFS Wasn't Enough
Summit Therapeutics centers on ivonescimab, a bispecific antibody blocking both PD-1 and VEGF in one molecule, targeting non-small cell lung cancer and colorectal cancer across multiple ongoing Phase 3 trials. The FDA's rejection of the lung cancer BLA was precise rather than sweeping. The double-blind Phase 3 trial met its PFS primary endpoint, the drug showed no new safety signals, and the FDA's objection was narrow: progression-free survival improvement unaccompanied by overall survival gains cannot, on its own, establish a positive benefit-risk profile. Whether the FDA's evidentiary bar applies only to this trial design or to the broader program, HARMONi-3 will provide the answer.
The Co-CEO Signal
On the day of the rejection, Co-CEOs Robert W. Duggan and Mahkam Zanganeh each exercised 500,000 stock options at $1.06 per share; COO and CFO Manmeet Singh Soni added 100,000 at $1.37, bringing total insider option exercises to 1.1 million shares. That strike reflects older compensation grants rather than new open-market commitments, but the timing aligns option realization with the stock's fifth consecutive down day. Summit carries $630 million in cash against minimal debt of $20 million. AstraZeneca put in $2 billion in equity, as disclosed in a September 29, 2026 8-K.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| SMMT | $8.5B | n/a | -29.7% |
| VKTX | $3.4B | n/a | -29.0% |
| RVMD | $35.1B | n/a | +136.4% |
| IOVA | $3.4B | n/a | +209.4% |
| IBRX | $6.6B | n/a | +184.8% |
| BBIO | $14.9B | n/a | +17.9% |
What HARMONi-3 Needs to Deliver
Analysts have not declared the FDA's ruling fatal. Jefferies upgraded to Buy with a $25 target, naming the HARMONi-3 PFS readout as the thesis checkpoint. Citi held its Buy at $40-$43, citing AstraZeneca's equity backing as a financing buffer. Bernstein moved to Market Perform at $11.90, barely above the current price. The consensus of $29.47 implies roughly 177% upside, with every target built on a DCF model discounting a commercial launch that now has no U.S. regulatory path in the near term. The figure that changes the setup: overall survival data from HARMONi-3, the bar the FDA has now put on record. Run the free Summit Therapeutics Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did FDA reject Summit Therapeutics' ivonescimab?
The FDA rejected the ivonescimab BLA for non-small cell lung cancer because progression-free survival improvements without overall survival gains do not establish a positive benefit-risk profile. While the Phase 3 trial met its primary PFS endpoint and showed no new safety signals, the FDA's requirement is now clear: overall survival data is needed to demonstrate effectiveness.
How much did SMMT stock fall after the FDA rejection?
SMMT fell 16.47% on November 16 (the rejection day) and an additional 8.93% on November 17, reaching $10.64. This two-day decline pushed the stock to a 52-week intraday low.
Why did insiders exercise options on the rejection day?
Co-CEOs Robert W. Duggan and Mahkam Zanganeh each exercised 500,000 options at $1.06 per share, while COO and CFO Manmeet Singh Soni exercised 100,000 at $1.37, bringing total insider exercises to 1.1 million shares. However, the $1.06 strike reflects older compensation grants rather than new commitments; the timing aligns with the stock's fifth consecutive down day.
Why is HARMONi-3 important for Summit Therapeutics?
HARMONi-3 is the upcoming trial readout that Jefferies named as its Buy thesis checkpoint with a $25 target. The FDA's new efficacy bar is overall survival data from HARMONi-3. The analyst consensus target of $29.47 implies roughly 177% upside, with every target built on favorable results from this trial.
What's Summit Therapeutics' cash position?
Summit carries a cash position of $630 million against minimal debt of $20 million. Additionally, AstraZeneca invested $2 billion in the company in September 2026, which Citi cited as a financing buffer supporting its Buy rating.
The FDA rejected Summit Therapeutics' Biologics License Application for ivonescimab in lung cancer on November 15–16, ruling that progression-free survival data could not establish effectiveness without a statistically significant improvement in overall survival. The stock hit a new 52-week intraday low of $11.54 on November 16 and has since fallen further to $10.64 — yet both Co-CEOs exercised stock options at $1.06 per share on the exact same day as the rejection.